Physician profile
Edward Borchard
NPI 1326005893
$5,465.67
in general payments reported to CMS, 2019-2025
24 companies · $726 in 2025
The $726 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $301 · 2021: $1,761 · 2022: $765 · 2023: $461 · 2024: $802 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $1,140.00 | 2021 | |
| Ironshore Pharmaceuticals INC. | $604.58 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $560.56 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $478.54 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $452.81 | 2021-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $441.52 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $352.30 | 2019-2025 | Bexsero, Pediarix |
| Pfizer INC. | $281.26 | 2019-2025 | |
| Sanofi Pasteur INC. | $218.51 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.49 | 2020-2022 | |
| Alk-Abello, INC | $143.74 | 2023-2024 | Ragwitek, Odactra, Grastek |
| Ipsen Biopharmaceuticals, INC | $124.69 | 2025 | Bylvay |
| Genentech USA, INC. | $97.92 | 2019 | |
| Biogen, INC. | $96.19 | 2024 | Spinraza |
| Neos Therapeutics, Lp | $74.39 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $45.10 | 2025 | Jornay Pm |
| Cumberland Pharmaceuticals, INC. | $40.83 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $40.02 | 2025 | Relexxii |
| Shire North American Group INC | $27.91 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $19.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.54 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.36 | 2019 | |
| Adlon Therapeutics L.P. | $13.59 | 2020 | |
| Galderma Laboratories, L.P. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Borchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.